

Proposed new classification of monoclonal antibodies for antineoplastic treatment (currently classified in L01XC), decided March 2021

| New ATC code | ATC level name | Current ATC code |
|---------------------|---|-------------------------|
| L01F | MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES | |
| L01FA | CD20 (Clusters of Differentiation 20) inhibitors | |
| L01FA01 | rituximab | L01XC02 |
| L01FA02 | ofatumumab | L01XC10 |
| L01FA03 | obinutuzumab | L01XC15 |
| L01FB | CD22 (Clusters of Differentiation 22) inhibitors | |
| L01FB01 | inotuzumab ozogamicin | L01XC26 |
| L01FB02 | moxetumomab pasudotox | L01XC34 |
| L01FC | CD38 (Clusters of Differentiation 38) inhibitors | |
| L01FC01 | daratumumab | L01XC24 |
| L01FC02 | isatuximab | L01XC38 |
| L01FD | HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors | |
| L01FD01 | trastuzumab | L01XC03 |
| L01FD02 | pertuzumab | L01XC13 |
| L01FD03 | trastuzumab emtansine | L01XC14 |
| L01FD04 | trastuzumab deruxtecan | L01XC41 |
| L01FD05 | trastuzumab duocarmazine | -- |
| L01FE | EGFR (Epidermal Growth Factor Receptor) inhibitors | |
| L01FE01 | cetuximab | L01XC06 |
| L01FE02 | panitumumab | L01XC08 |
| L01FE03 | necitumumab | L01XC22 |
| L01FF | PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors | |
| L01FF01 | nivolumab | L01XC17 |
| L01FF02 | pembrolizumab | L01XC18 |
| L01FF03 | durvalumab | L01XC28 |
| L01FF04 | avelumab | L01XC31 |
| L01FF05 | atezolizumab | L01XC32 |
| L01FF06 | cemiplimab | L01XC33 |
| L01FF07 | dostarlimab | L01XC40 |
| L01FF08 | prolgolimab | L01XC42 |
| L01FF09 | tislelizumab | -- |
| L01FF10 | retifanlimab | -- |
| L01FG | VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors | |
| L01FG01 | bevacizumab | L01XC07 |
| L01FG02 | ramucirumab | L01XC21 |
| L01FX | Other monoclonal antibodies | |
| L01FX01 | edrecolomab | L01XC01 |
| L01FX02 | gemtuzumab ozogamicin | L01XC05 |
| L01FX03 | catumaxomab | L01XC09 |
| L01FX04 | ipilimumab | L01XC11 |
| L01FX05 | brentuximab vedotin | L01XC12 |

| | | |
|---------|-----------------------|---------|
| L01FX06 | dinutuximab beta | L01XC16 |
| L01FX07 | blinatumomab | L01XC19 |
| L01FX08 | elotuzumab | L01XC23 |
| L01FX09 | mogamulizumab | L01XC25 |
| L01FX10 | olaratumab | L01XC27 |
| L01FX11 | bermekimab | L01XC29 |
| L01FX12 | tafasitamab | L01XC35 |
| L01FX13 | enfortumab vedotin | L01XC36 |
| L01FX14 | polatuzumab vedotin | L01XC37 |
| L01FX15 | belantamab mafodotin | L01XC39 |
| L01FX16 | oportuzumab monatox | -- |
| L01FX17 | sacituzumab govitecan | -- |
| L01FX18 | amivantamab | -- |